Multiple myeloma (MM) is a complex hematological malignancy with significant unmet needs. While conventional therapies have significantly improved patient survival, the disease remains incurable.
This review, published in the journal Molecular Biomedicine and led by Qizhong Lu, Donghui Yang, Ting Niu, and Aiping Tong, explores the multifaceted nature of MM and the promising potential of targeted therapies.
The authors delve into the key signaling pathways that drive MM pathogenesis, including the PI3K/AKT/mTOR, RAS/MAPK, JAK/STAT, Wnt/β-catenin, and NF-κB pathways. Aberrant activation of these pathways contributes to the proliferation, survival, migration, and drug resistance of myeloma cells. The review provides a comprehensive overview of the roles of these pathways in MM, highlighting their potential as therapeutic targets.
The authors also discuss the progress made in developing targeted immunotherapies for MM. This includes monoclonal antibodies, ADCs, BsAbs, immune checkpoint inhibitors, CAR-T cells, CAR-NK cells, and TCR-T cells. The review explores the mechanisms of action of these therapies, their efficacy in clinical trials, and the challenges that remain in their development.
Key findings from the review include:
The authors conclude by emphasising the need for continued research and development of targeted therapies for MM. They call for a focus on enhancing the specificity and efficacy of these therapies, developing more affordable treatment options, and investigating combination therapies to address resistance mechanisms.
They also emphasise the importance of personalising treatment regimens for individual patients.
Source: Sichuan International Medical Exchange and Promotion Association
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.